Cell Therapy of Severe Ischemia in People with Diabetic Foot Ulcers—Do We Have Enough Evidence?

This current opinion article critically evaluates the efficacy of autologous cell therapy (ACT) for chronic limb-threatening ischemia (CLTI), especially in people with diabetes who are not candidates for standard revascularization. This treatment approach has been used in ‘no-option’ CLTI in the las...

Descripción completa

Detalles Bibliográficos
Autores principales: Dubský, Michal, Husáková, Jitka, Sojáková, Dominika, Fejfarová, Vladimíra, Jude, Edward B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Current Opinion
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10590286/
https://www.ncbi.nlm.nih.gov/pubmed/37740111
http://dx.doi.org/10.1007/s40291-023-00667-w
_version_ 1785123958697230336
author Dubský, Michal
Husáková, Jitka
Sojáková, Dominika
Fejfarová, Vladimíra
Jude, Edward B.
author_facet Dubský, Michal
Husáková, Jitka
Sojáková, Dominika
Fejfarová, Vladimíra
Jude, Edward B.
author_sort Dubský, Michal
collection PubMed
description This current opinion article critically evaluates the efficacy of autologous cell therapy (ACT) for chronic limb-threatening ischemia (CLTI), especially in people with diabetes who are not candidates for standard revascularization. This treatment approach has been used in ‘no-option’ CLTI in the last two decades and more than 1700 patients have received ACT worldwide. Here we analyze the level of published evidence of ACT as well as our experience with this treatment method. Many studies have shown that ACT is safe and an effective method for patients with the most severe lower limb ischemia. However, some trials did not show any benefit of ACT, and there is some heterogeneity in the types of injected cells, route of administration and assessed endpoints. Nevertheless, we believe that ACT plays an important role in a comprehensive treatment of patients with diabetic foot and severe ischemia.
format Online
Article
Text
id pubmed-10590286
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-105902862023-10-23 Cell Therapy of Severe Ischemia in People with Diabetic Foot Ulcers—Do We Have Enough Evidence? Dubský, Michal Husáková, Jitka Sojáková, Dominika Fejfarová, Vladimíra Jude, Edward B. Mol Diagn Ther Current Opinion This current opinion article critically evaluates the efficacy of autologous cell therapy (ACT) for chronic limb-threatening ischemia (CLTI), especially in people with diabetes who are not candidates for standard revascularization. This treatment approach has been used in ‘no-option’ CLTI in the last two decades and more than 1700 patients have received ACT worldwide. Here we analyze the level of published evidence of ACT as well as our experience with this treatment method. Many studies have shown that ACT is safe and an effective method for patients with the most severe lower limb ischemia. However, some trials did not show any benefit of ACT, and there is some heterogeneity in the types of injected cells, route of administration and assessed endpoints. Nevertheless, we believe that ACT plays an important role in a comprehensive treatment of patients with diabetic foot and severe ischemia. Springer International Publishing 2023-09-22 2023 /pmc/articles/PMC10590286/ /pubmed/37740111 http://dx.doi.org/10.1007/s40291-023-00667-w Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Current Opinion
Dubský, Michal
Husáková, Jitka
Sojáková, Dominika
Fejfarová, Vladimíra
Jude, Edward B.
Cell Therapy of Severe Ischemia in People with Diabetic Foot Ulcers—Do We Have Enough Evidence?
title Cell Therapy of Severe Ischemia in People with Diabetic Foot Ulcers—Do We Have Enough Evidence?
title_full Cell Therapy of Severe Ischemia in People with Diabetic Foot Ulcers—Do We Have Enough Evidence?
title_fullStr Cell Therapy of Severe Ischemia in People with Diabetic Foot Ulcers—Do We Have Enough Evidence?
title_full_unstemmed Cell Therapy of Severe Ischemia in People with Diabetic Foot Ulcers—Do We Have Enough Evidence?
title_short Cell Therapy of Severe Ischemia in People with Diabetic Foot Ulcers—Do We Have Enough Evidence?
title_sort cell therapy of severe ischemia in people with diabetic foot ulcers—do we have enough evidence?
topic Current Opinion
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10590286/
https://www.ncbi.nlm.nih.gov/pubmed/37740111
http://dx.doi.org/10.1007/s40291-023-00667-w
work_keys_str_mv AT dubskymichal celltherapyofsevereischemiainpeoplewithdiabeticfootulcersdowehaveenoughevidence
AT husakovajitka celltherapyofsevereischemiainpeoplewithdiabeticfootulcersdowehaveenoughevidence
AT sojakovadominika celltherapyofsevereischemiainpeoplewithdiabeticfootulcersdowehaveenoughevidence
AT fejfarovavladimira celltherapyofsevereischemiainpeoplewithdiabeticfootulcersdowehaveenoughevidence
AT judeedwardb celltherapyofsevereischemiainpeoplewithdiabeticfootulcersdowehaveenoughevidence

Ejemplares similares